Aktuellt
SENASTE
Redeye significantly lowers its base case following an increasingly precarious situation in Orphazyme, which will continue to push the share down from current levels quite considerably. Our new Base Case is set at DKK 3 (earlier indicative range of DKK 6-10) compared to today’s price of DKK 5.5. Our new valuation disregards all clinical development programs and more or less solely reflect its current cash position.
LÄS MER
